Update Note: This article reports new post-hoc findings from the ATTAIN-1 trial of Foundayo (orforglipron), released by Eli Lilly on October 1, 2026, and published in the journal Diabetes, Obesity and Metabolism, following MedicalDaily's earlier coverage of the drug's approval and diabetes trials.
Adults with obesity or overweight who took the highest dose of Eli Lilly's once-daily weight loss pill Foundayo had a 57% lower predicted 10-year risk of developing type 2 diabetes than those on placebo, according to new analyses of the ATTAIN-1 trial. The figure comes from a risk calculator, not from counting people who actually developed diabetes. Lilly sponsored the trial and announced the results.
The distinction matters for millions of American households. Many adults considering a GLP-1 pill worry about a parent's diabetes or their own borderline blood sugar. These findings offer a possible signal about long-term benefit, but they do not yet show that the pill prevents diabetes or heart disease in real patients.
For families weighing cost, coverage, and side effects, the weight loss is proven while long-term disease prevention remains a projection. That gap is the central question here.
Risk Engines Behind the 57% Figure
The new numbers come from post-hoc analyses, meaning researchers examined the trial data after the main study ended, using questions that were not part of its original design. According to Lilly's announcement, researchers fed participants' measurements at 72 weeks into two established risk engines. These tools estimate a person's future chance of disease from factors such as weight, blood sugar, and blood pressure.
For type 2 diabetes, the team used the Cardiometabolic Disease Staging (CMDS) risk engine. For cardiovascular disease, it used a BMI-based version of the Framingham risk score, a long-standing heart risk calculator. Both estimate risk over 10 years.
At the 17.2 mg dose, predicted 10-year diabetes risk fell 57% compared with placebo, and predicted cardiovascular risk fell 18%. Lower doses showed smaller predicted effects. The 9 mg dose was linked to a 50% predicted diabetes reduction and a 15% cardiovascular reduction, while the 5.5 mg dose was tied to 45% and 13%, respectively.
Thomas Seck, M.D., senior vice president of product development at Lilly Cardiometabolic Health, said in the release that "these additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss." Seck also said treating obesity and its downstream consequences can lower health care costs, a claim this analysis did not test.
Evidence Limits and Lilly's Role in the Trial
ATTAIN-1, registered on ClinicalTrials.gov as NCT05869903, was a Phase 3, randomized, double-blind, placebo-controlled study of 3,127 adults with obesity, or overweight plus a weight-related health problem. None had diabetes when they enrolled. At 72 weeks, the trial was far too short to show how many participants would develop diabetes or heart disease over a decade.
That is the key limitation. The 57% figure is an estimate of what might happen if the improvements seen at 72 weeks hold, and if the risk engine accurately predicts outcomes for people losing weight on a medication. Neither assumption has been confirmed. Post-hoc analyses are also more prone to chance findings than a trial's main, prespecified goals.
Funding is the second caution. Eli Lilly sponsored ATTAIN-1, makes Foundayo, and publicized these results. The findings appeared in a peer-reviewed journal, but no independent group has yet repeated the modeling. The study showed an association between the drug's effects on risk factors and lower predicted risk; it did not prove that Foundayo prevents disease.
A separate Lilly trial compared Foundayo with insulin in people who already have type 2 diabetes, and MedicalDaily reported that the pill matched insulin on heart safety while cautioning that its lower death rate came from secondary analyses. Neither study settles the long-term prevention question for people without diabetes.
Prediabetes Families, Prices and Insurance Hurdles
The potential audience is large. The CDC estimates that 115.2 million U.S. adults had prediabetes in 2023, including 31.3 million people ages 65 and older. Another 11 million adults had diabetes without knowing it. Adults with obesity, high blood pressure, or a family history of diabetes are most likely to follow this research.
The FDA approved Foundayo on April 1, 2026, for adults with obesity, or some adults with overweight and weight-related medical problems, alongside diet and exercise. It is approved to reduce and maintain weight loss. It is not approved to prevent diabetes or heart disease, and this analysis does not change that label. In ATTAIN-1, adults on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, among those who stayed on treatment, compared with 0.9% on placebo.
Cost remains the practical barrier for many households. Lilly said in its availability announcement that self-pay prices through LillyDirect start at $149 a month for the lowest dose, that eligible people with commercial coverage may pay as little as $25 a month with a savings card, and that a $50 monthly Medicare Part D price would begin July 1, 2026. Lilly did not list self-pay prices for every dose, and coverage varies by plan.
Safety also belongs in any household decision. The drug's labeling warns of possible thyroid tumors, including cancer, as well as pancreatitis, gallbladder problems, serious stomach problems, dehydration that can affect the kidneys, low blood sugar, and allergic reactions. Severe, persistent belly pain, signs of an allergic reaction, or a lump or swelling in the neck warrant prompt medical attention, while milder nausea or diarrhea is worth discussing with a prescriber.
Adults concerned about diabetes can ask a clinician for an A1C or fasting glucose test, especially if they have risk factors. People already taking a GLP-1 medicine should not stop or switch based on this news without speaking with a health care professional. Those considering Foundayo can ask their insurer about prior authorization rules and compare the savings card, self-pay, and Medicare options before filling a prescription.
Firmer answers will require long-term studies that count actual diabetes diagnoses and heart events. Until then, the analysis offers an encouraging projection from the drugmaker's own trial, but the proven benefit of Foundayo remains weight loss, and the decision to use it is best made with a clinician who knows a person's full health history.
Key Questions Answered
What did the new Foundayo analysis find?
Using two risk calculators, researchers estimated that the 17.2 mg dose of Foundayo was linked to a 57% lower predicted 10-year risk of type 2 diabetes and an 18% lower predicted 10-year cardiovascular risk compared with placebo, based on measurements taken after 72 weeks.
Did the trial show that Foundayo prevents diabetes?
No. The analysis did not count actual diabetes cases. It projected future risk from changes in weight, blood sugar, and other factors, so the result is an estimate rather than proof of prevention.
Who paid for the research?
Eli Lilly, which makes Foundayo, sponsored the ATTAIN-1 trial and announced the results. The analysis was published in Diabetes, Obesity and Metabolism, but it has not been independently repeated.
Is Foundayo approved to prevent diabetes or heart disease?
No. The FDA approved it in April 2026 for weight reduction and maintenance in adults with obesity, or overweight with weight-related health problems, along with diet and exercise.
How much does Foundayo cost?
Lilly says self-pay prices start at $149 a month for the lowest dose. Eligible commercially insured patients may pay as little as $25 a month with a savings card, and Lilly lists a $50 monthly Medicare Part D price starting July 1, 2026.
What should people with prediabetes do now?
Talk with a clinician about blood sugar testing and proven prevention steps such as diet changes and physical activity. Anyone already on a GLP-1 medicine should not stop or change treatment without speaking with a health care professional.
Published by Medicaldaily.com
